Vapotherm to expand nasal cannula production in response to Covid-19

5 June 2020 (Last Updated June 5th, 2020 16:36)

Vapotherm is set to scale up capital equipment manufacturing capabilities to increase the production of its Precision Flow systems.

Vapotherm to expand nasal cannula production in response to Covid-19
Vapotherm scales up manufacturing capabilities to meet the potential increase in demand for its Precision Flow Hi-VNI system in the event of fresh waves of Covid-19 pandemic. Credit: UN Women / Pathumporn Thongking.

Vapotherm is set to scale up capital equipment manufacturing capabilities to increase the production of its Precision Flow systems.

The move is in response to an anticipated increase in demand for the company’s Precision Flow Hi-VNI system in the event of new waves of Covid-19 pandemic.

The company intends to scale up the production by up to 20X above pre-Covid-19 pandemic levels with additional 350 manufacturing jobs at its New Hampshire, US, facility.

Vapotherm’s Precision Flow Hi-VNI system is an advanced high-flow nasal cannula (HFNC) system, which uses high velocity to treat respiratory distress related to Covid-19 disease.

It offers high flow at a high velocity, rapidly flushing the dead space in the limited time between breaths when respiratory rates are elevated.

A number of public health authorities and medical speciality societies, including Center for Disease Control (CDC), the National Institutes of Health (NIH), the Society of Critical Care Medicine (SCCM) and the American College of Emergency Physicians (ACEP) have recommended HFNC over early invasive mechanical ventilation when possible.

Commenting on the latest development, Vapotherm CEO Joe Army said: “The Covid-19 pandemic has greatly accelerated a process we were already seeing of respiratory experts recognising the benefits of our Precision Flow Hi-VNI system for treating patients with all types of respiratory distress.

“As hospitals and governments across the United States and around the world prepare for potential future waves of Covid-19 patients and subsequent pandemics, involving respiratory disease, we are expanding our manufacturing capabilities to be in a position to meet the needs of hospitals and patients for our therapy.”